Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: Is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study

Author： Kellokumpu-Lehtinen P.   Bergh J.   Salminen E.   Wiklund T.   Lehtinen S.   Aronen P.   Sintonen H.  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.46, Iss.2, 2007-01, pp. : 146-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

By Lalisang R.   Erdkamp F.   Rodenburg C.   Knibbeler-van Rossum C.   Nortier J.   Bochove A.   Slee P.   Voest E.   Wils J.   Wals J.   Loosveld O.   Smals A.   Blijham G.   Tjan-Heijnen V.   Schouten H.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 2, 2011-07 ,pp. : 437-445

Springer Publishing Company

Access to resources Recommend Favorite

Paclitaxel-containing High-dose Chemotherapy in High-risk Breast Cancer Patients

By Greinix Hildegard T.   Linkesch Werner   Seifert Manfred   Kubista Ernst   Czerwenka Klaus   Elahi Fariborz   Zielinski Christoph   Hoecker Paul   Steger Günther   Schulenburg Axel   Neumeister Geralt   Rabitsch Werner   Jakesz Raimund   Kalhs Peter  

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial

By Verrill Mark  

The Women's Oncology Review, Vol. 5, Iss. 1, 2005-03 ,pp. : 41-43

Informa Healthcare

Access to resources Recommend Favorite

Acute and Late Toxicity Following Adjuvant High-Dose Chemotherapy for High-Risk Primary Operable Breast Cancer A Quality Assessment Study

By Svane Inge M.   Homburg Keld M.   Kamby Claus   Nielsen Dorte L.   Roer Ole   Sliffsgaard Dorte   Johnsen Hans E.   Hansen Steen W.  

Acta Oncologica, Vol. 41, Iss. 7-8, 2002-11 ,pp. : 675-683

Informa Healthcare

Access to resources Recommend Favorite

High-dose Chemotherapy in Tumours Other Than Lymphomas and Breast Cancer

By Droz J.P.   Biron P.  

European Journal of Cancer, Vol. 31, Iss. 5, 1995-01 ,pp. : 811-812

Elsevier

Access to resources Recommend Favorite